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R adiotherapy for breast cancer reduces local recur-rence and improves survival [1 , 2].  To date,  var-
ious irradiation techniques have been applied clinically 
[3-19],  and advances in irradiation techniques have 
reduced adverse events for organs at risk (OAR) [5 , 16].  
Different irradiation techniques can be used to modify 
the dose distributions to the skin,  lungs,  and heart,  
which also affects the rate of adverse events at these 
sites.  Skin damage is known to be associated with high 
doses in the irradiation field [10 , 12 , 13].  The mean 
heart dose (MHD) correlates with the risk of adverse 
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Reports on irradiation dose distribution in breast cancer radiotherapy with sufficient sample size are limited in 
Asian patients.  Elucidating dose distribution in Asian patients is particularly important as their breast volume 
differs compared to patients in Europe and North America.  Here,  we examined dose distribution in the irradi-
ation field relative to breast volume for three irradiation methods historically used in our facility.  We investi-
gated the influence of breast volume on each irradiation method for Asian women.  A total of 573 women with 
early-stage breast cancer were treated with breast-conserving surgery and adjuvant radiotherapy.  Three meth-
ods were compared: wedge (W),  field-in-field (FIF),  and wedge-field-in-field (W-FIF).  In patients with small 
breast volume,  FIF decreased low- and high-dose areas within the planning target volume,  and increased opti-
mal dose area more than W.  In patients with medium and large breast volumes,  FIF decreased high-dose area 
more than W.  The absolute values of correlation coefficients of breast volume to low-,  optimal-,  and high-dose 
areas and mean dose were significantly lower in FIF than in W.  The correlation coefficients of V107% were 0.00 
and 0.28 for FIF and W,  respectively.  FIF is an excellent irradiation method that is less affected by breast vol-
ume than W in Asian breast cancer patients.
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events for both the heart and coronary arteries [13-17].  
In addition,  the risk of radiation pneumonitis is pro-
portional to the mean lung dose [13 , 14].
Breast cancer patients with large breast volume have 
been reported to experience uneven dose distributions 
[8 , 10] and higher rates of adverse events [5 , 9 , 10 , 13] 
than those with smaller breast volume.  Nonetheless,  
few large studies have compiled the irradiation dose 
distributions for Asian women with breast cancer,  
whose breast volumes tend to be smaller than those of 
Western women [18].
In this study,  we reviewed the breast volumes and 
irradiation dose distributions for Asian women with 
breast cancer who were treated at our institution using 
one of three different irradiation methods: the wedge 
method (W),  field-in-field method (FIF),  or wedge-
field-in-field method (W-FIF),  which combines the W 
and FIF methods.  We then analyzed the relation 
between the differences in breast volume and the dose 
distribution for each irradiation method,  and compared 
the results with data acquired from a literature review.  
In this way,  we attempted to determine which irradia-
tion method is least affected by differences in breast 
volume.  In addition,  we aimed to grasp the actual irra-
diation doses for targets and OARs of a large number of 
Asian breast cancer patients,  compare them with past 
literature data,  and use the results for future improve-
ment.
Patients and methods
Patients. This study evaluated 577 women with 
breast cancer without distant metastasis,  who were 
treated with breast-conserving surgery and adjuvant 
radiation therapy at Okayama University Hospital 
between April 2008 and December 2016.  The exclusion 
criteria were simultaneous treatment of bilateral breast 
cancer,  irradiation treatment of the regional lymph 
nodes,  or hypofractionated irradiation.  The Ethical 
Review Board of our institute approved the use of anon-
ymous post-radiation therapy data for the study (No. 
KEN 1907-027).  The study was conducted in accor-
dance with the 2013 revised Helsinki Declaration.
Radiation treatment. Each patient received 
whole breast radiation therapy at a total prescribed dose 
of 50 Gy in 25 fractions (2 Gy per fraction,  5 times a 
week).  Some patients received a 10 or 16 Gy boost irra-
diation to the tumor bed.  Computed tomography (CT) 
imaging was performed with patients in a supine posi-
tion,  with one or both arms extended overhead,  and a 
foam cushion wedge under the knee,  with or without 
fasteners.  CT with free-breathing was performed using 
an Asteion Super 4 Edition multi-slice CT scanner 
(Toshiba Medical Systems,  Tochigi,  Japan),  and recon-
struction was performed on 2-mm thick slices.  In order 
to facilitate contour setting in the CT image during the 
setting of the irradiation field,  radiopaque markers 
were placed on the following body surface landmarks:  
the suprasternal notch,  sternal midline,  midaxillary 
line,  1 cm inferior to the inframammary fold,  surgical 
scars,  nipples,  and the edges of palpable breast tissue.  
The CT images were then transferred to a treatment 
planning system,  CMS XiO Ver 4.3.4 (Computerized 
Medical Systems,  Maryland Heights,  MO,  USA).
The irradiation field was preset following the supra-
sternal notch,  the sternal midline,  the midaxillary line,  
and 1 cm inferior of the inframammary fold,  and 
extended 2 cm on the skin side.  The preset irradiation 
field was verified and modified to include the planning 
target volume (PTV) and breast PTV evaluation (BPe) 
in an irradiation field that would result in three-dimen-
sional conformal radiotherapy treatment.  The PTV was 
pre-set three-dimensionally as a 5 mm area inside the 
irradiation field and excluded the following: the 
patient’s extracorporeal air,  tissue 5 mm below the skin,  
the lung and the chest wall between the lung and the 
anterior rib edge.  The BPe was determined according to 
the clinical target volume and PTV which were defined 
by the clinical research protocol RTOG 1005 <https://
www.rtog.org/ClinicalTrials/ProtocolTable/Study 
Details.aspx?action=open File&FileID=9366 (accessed 
July 11, 2020)>.
The axillary lymph node levels I,  II,  and III,  and 
OAR were contoured following the RTOG-approved 
consensus guidelines for delineating breast cancer tar-
gets and normal structures <https://www.rtog.org/Core 
Lab/ContouringAtlases/BreastCancerAtlas.aspx 
(accessed July 11, 2020)>.  The outlined OAR were the 
lungs and the heart.  The lungs were outlined by auto-
matic segmentation with manual verification.  The con-
tour of the heart began slightly below the level at which 
the pulmonary trunk diverged into the left and right 
pulmonary arteries,  and was contoured to the lowest 
extent near the diaphragm in all subsequent slices.  
Treatment was planned in an isocentric manner using 
the CMS XiO treatment planning system.  Beam ener-
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gies of 4,  6,  and 10 MV were used as high energy 
X-rays from a Linac (Mevatron M2/6327,  Primus High 
Energy KD2/7467,  and ONCOR High Energy ONCR-
K; Toshiba Medical Systems,  Tochigi,  Japan).
Three irradiation methods were performed.  The W 
was used as follows: 2 tangential opposing wedge half 
beams were generated to cover the field.  Gantry and 
collimator angles were adjusted using the beam’s eye 
view of the treatment planning system to minimize 
heart and lung irradiation while maximizing the target 
volume range.  The reference point (RP) was set at the 
level of the nipple,  or at an intermediate level between 
the upper and lower ends of the irradiation field.  A 
physical wedge filter was used on the opposing tangen-
tial beams to improve the target dose distribution.  The 
W-FIF was used as follows.  When the wedge filter alone 
could not improve the dose distribution,  it was 
improved by adding an additional tangential field-in-
field to avoid hot spots.  The RP was set at the level of 
the nipple,  or at an intermediate level between the 
upper and lower ends of the irradiation field.  FIF was 
used as follows.  Two opposing tangential fields were set 
without a wedge filter.  The RPs were set at the point on 
a slice at an intermediate level between the upper and 
lower borders of the field,  the deepest point on a slice 
2 cm inside from the upper border of the field,  or both 
simultaneously.  The main field was copied as a subfield,  
and a multileaf collimator was set up to protect the areas 
of the breast that received high doses.  The PTV and BPe 
doses were set according to the ICRU criteria such that 
the dose distribution was 95-107% of the prescribed 
dose,  and the OAR dose was as low as possible.  The 
irradiation methods W,  W-FIF,  and FIF were used for 
patients in this order sequentially over the research 
period.
The dosimetric parameters of the targets evaluated 
in this study were as follows: mean dose of PTV and 
BPe,  V0-95% (volume fraction receiving less than 95% 
of the prescribed dose); V95-107% (volume fraction of 
95-107% of the prescribed dose); V107% (volume frac-
tion receiving more than 107% of the prescribed dose);  
V105% (volume fraction of 105% or more of the pre-
scribed dose); and the mean dose to axillary lymph 
node levels I,  II,  and III.  The dosimetric parameters of 
the OAR were as follows: ipsilateral pulmonary (ip) 
mean dose,  ipV20 (volume fraction receiving ≥ 20 Gy),  
and ipV30 (volume fraction receiving ≥ 30 Gy); MHD,  
V10 (volume fraction receiving ≥ 10 Gy),  and V20 (vol-
ume fraction receiving ≥ 20 Gy) of the heart; and the 
maximum doses for the left anterior descending coro-
nary artery (LAD),  left circumflex coronary artery 
(CCA),  and right coronary artery (RCA).
Data collection and statistical analysis. For each 
patient,  we analyzed the patient background factors 
and the dosimetric parameters obtained from the dose- 
volume histogram in the radiation treatment plan.  
BellCurve for Excel (Social Survey Research Informa-
tion Co.,  Ltd.,  Tokyo) was used for statistical analysis.  
Differences in patient background factors and dosime-
try parameters were compared using the chi-square test 
or Kruskal-Wallis test followed by the Scheffe method,  
depending on the irradiation method used.  Differences 
in dosimetry parameters,  etc.,  by irradiation methods 
and breast volume were also compared using the 
Kruskal-Wallis test and the Scheffe method.
In order to evaluate the relationship between breast 
volume and dose parameter for each irradiation 
method,  Spearman’s rank correlation coefficient (rs) was 
calculated,  and the significance was tested.  The abso-
lute value of rs was defined as “very weak” 0-0.19;  
“weak” 0.20-0.39; “moderate” 0.40-0.59; “strong” 
0.60-0.79; and “very strong” 0.80-1.  Fisher Z-transform 
with a two-sided test was performed to test for signifi-
cant differences in rs for each treatment method.  A 
P-value < 0.05 was considered statistically significant.  
Calculation of the 95% confidence interval (CI) for rs 
was performed using langtest < http://langtest.jp/shiny/
cor/ (accessed September 30, 2020)>.
Results
Between 2008 and 2016,  577 patients between the 
ages of 24 and 82 (median,  55) were treated according 
to the inclusion criteria.  Four patients treated without 
using a W or FIF technique were excluded from this 
study due to insufficient sample size; thus,  a total of 
573 patients were included in the final analysis.  The W,  
W-FIF,  and FIF were used on 109,  69,  and 395 patients,  
respectively.
Table 1 presents the background factors for each 
irradiation method.  The mean age of the patients was 
55 ± 11 years.  There were no statistically significant dif-
ferences in age or tumor site,  as defined by the interna-
tional classification of diseases for oncology <https://
apps.who.int/iris/bitstream/handle/10665/96612/ 
9789241548496_eng.pdf?sequence=1 (accessed September 
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26, 2020)>,  among the three irradiation groups.  BPe 
volume was used to evaluate the breast volume,  and the 
breast volume for the W-FIF group was larger than that 
for the W group.  Regarding the background factors of 
patients with left breast cancer,  there were no signifi-
cant differences in age,  tumor site or breast volume 
among the three irradiation groups (Table 1).
Breast volume was divided into 3 groups (small:  
< 360; medium: ≥ 360 and ≤ 568; large: > 568 [cm3]) 
according to the same criteria in previous reports [6].  
The dose parameters for each group are summarized in 
Table 2.  With regards to the target,  in patients with a 
small breast volume,  FIF decreased low and high dose 
areas within the PTV and increased the optimal dose 
area more than W.  In patients with medium and large 
breast volumes,  FIF decreased the high dose area more 
than W.  As breast volume increased,  both FIF and W 
decreased the low dose area.
The correlation coefficients (rs) and 95% CIs between 
the breast volume and each dose parameter are listed in 
Table 3 for each irradiation method.  With regards to 
the evaluation of rs for the targets,  the mean dose with 
W and W-FIF and the low-dose area (V0-95%) with 
W-FIF were “weak”; the low-dose area (V0-95%) with 
W was “moderate”; and all parameters with FIF were 
“very weak”.  As a result of the Z conversion,  the abso-
lute values of rs were significantly lower with FIF than 
with W in the low-,  optimal-,  and high-dose areas and 
mean dose (Table 3).
With respect to irradiation to the lymph nodes,  W 
and W-FIF are the methods in which breast volume has 
a significant effect on dose distribution,  while distribu-
tion to the lymph nodes by FIF is not affected by breast 
volume (Table 3).
With respect to OAR (Table 2),  the ip mean lung 
dose decreased with increasing breast volume by all 
three irradiation methods.  The rs for all lung dose 
parameters (ip mean dose,  ipV20,  and ipV30) were 
“weak” for W and FIF,  and “moderate” for W-FIF.  No 
significant differences were found in these rs values by 
Z-transform (Table 3).  The MHD of FIF was smaller 
than that of W for patients with small breast volumes 
(Table 2).  The MHD increased in FIF as breast volume 
increased (Table 2).  The rs for the MHD (Table 3) was 
“moderate” for FIF,  “weak” for W-FIF,  and “very weak” 
for W.  The rs values for V10 and V20 (Table 3) were 
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Table 1　 Background factors for each irradiation method
All methods W W-FIF FIF Statistics (W vs W-FIF vs FIF)
All patients
　Patient 573 109 69 395
　Age 55±11 54±10 53±12 55±11 NS＊
　Tumor site in breast＃ NS＊＊
　　Upper-inner quadrant 161 29 18 114
　　Lower-inner quadrant 50 14 4 32
　　Upper-outer quadrant 278 44 37 197
　　Lower-outer quadrant 55 18 5 32
　　Central portion 29 4 5 20
　Breast volume (cm3) 442±254 410±234 532±308 435±246 P<0.05＊ (P<0.05ǂ)
Patients of left breast cancer
　Patient 296 49 40 207
　Age 55±11 55±10 55±13 55±11 NS＊
　Tumor site in breast＃ NS＊＊
　　Upper-inner quadrant 82 17 9 56
　　Lower-inner quadrant 30 8 3 19
　　Upper-outer quadrant 149 18 24 107
　　Lower-outer quadrant 16 4 2 10
　　Central portion 19 2 2 15
　Breast volume (cm3) 442±253 452±249 494±262 430±252 NS＊
Number with “±” indicates mean with standard deviation.  Numbers in “patient” and “tumor site in breast” indicate numbers of patients.  
＃,  International classification of diseases for oncology (third edition).
＊,  Kruskal-Wallis test; ＊＊,  Chi-square test; ǂ,  W vsW-FIF for Scheffeʼs method of Kruskal-Wallis test.
W,  wedge method; W-FIF,  wedge field-in-field method; FIF,  field-in-field method; NS,  not significant.
“very weak” and “very weak” in W,  “very weak” 
and “weak” in W-FIF,  and “weak” and “weak” in 
FIF,  respectively.  In the Z-transform,  the rs for 
the MHD was significantly different between FIF 
and W.
With regard to the coronary arteries,  the LAD 
had a higher dose than the CCA and RCA (Table 
4).  The rs of LAD with respect to breast volume 
was “very weak” for W and FIF,  and “weak” for 
W-FIF (Table 3).  No significant difference was 
found in these rs values by Z-transform (Table 3).
Table 4 summarizes the dose parameters for 
each irradiation method.  Regarding the target,  
the high-dose area in PTV and BPe was greater 
with W than with FIF.  The low-dose area in PTV 
and BPe was greater with W than with FIF.  In the 
OAR,  FIF decreased the MHD and maximum 
doses of the CCA and RCA significantly more than 
W and W-FIF.
Discussion
Few reports have examined the differences in 
irradiation techniques in a large number of breast 
cancer patients in Asia,  where breast volume is 
relatively small compared to Europe and North 
America.  In this study,  the characteristics of each 
irradiation method were analyzed statistically in a 
large number of cases in order to improve the reli-
ability of the data.  As a result,  it was clarified that 
FIF is an excellent irradiation method with a 
smaller high-dose area than that by W irrespective 
of breast volume.
In the studies from Asia (including Japan) [18] 
that have examined the differences in irradiation 
techniques,  the number of cases has been small 
(10 to < 100).  There are few reports of more than 
several hundred cases even in Europe and North 
America [4 , 6-10 , 12].  This study used a large 
number of cases,  573,  to compare treatments with 
previous reports [6] in Europe and North 
America.
The mean breast volume in European and 
North American patients is 518-1,063 (cm3) 
[6 , 12 , 19]; in contrast,  in this study of Asian 
patients,  the mean breast volume was 442 (cm3).  
Numerous studies have shown that large breast 
volume affects the high-dose area of the target 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































[8 , 10] and increases adverse skin effects [5 , 9 , 10 , 13].  
Morganti et al.  [6],  using the same 3 volumetric catego-
ries as in this study,  found that FIF decreased the high 
dose area more than W at any breast volume.  Similarly,  
in this study,  where we used the correlation coefficient 
for the target,  we found that the absolute values of rs 
were significantly lower in FIF than in W in the mean-
dose,  low-dose,  optimal-dose,  and high-dose areas.  It 
can be expected that using FIF to reduce the high-dose 
area could also decrease adverse skin events.  In patients 
with small breast volume,  FIF decreased not only the 
high-dose area but also the low-dose area,  and 
increased the optimal-dose area more than W,  suggest-
ing that FIF is a superior method.  The high-dose areas 
of all irradiation methods in this study were less irre-
spective of breast volume than those in Morganti et al.  
and other reports [6 , 9] from Europe and North 
America.
With regard to OAR,  as breast volume increased,  
the mean lung dose decreased with all irradiation meth-
ods,  and MHD increased with FIF.  Compared to previ-
ous papers [4 , 6],  the mean lung dose in this study was 
higher.  Moreover,  Osei et al.  reported lower ipV20 and 
ipV30 using state-of-the-art deep inspiration breath 
hold (DIBH) technology [8] compared to our results.  
The MHDs in this study were higher,  but the V10 and 
V20 were lower than those in previous papers using 
IMRT and FIF [4 , 6 , 19].  Osei et al.  also reported a 
lower V10 and V20 using the state-of-the-art DIBH 
technology [8] compared to our results.  In our study,  
the MHD of FIF was lower than those of W and W-FIF.
When using FIF,  the MHD is greatly affected by 
breast volume; thus,  it is desirable to use DIBH in 
patients with large breasts.  Oechsner et al.  [3] reported 
that DIBH reduced MHD by 31-63% compared to free 
breathing.  Beaton et al.  [16] reported that radiation- 
induced cardiac death by 10 years is low if the MHD is 
less than 3.3 Gy.  In this study,  18% (52/296) of the 
total,  29% (14/49) of W,  23% (9/40) of W-FIF,  and 
14% (29/207) of FIF cases had an MHD greater than 
3.3 Gy.  If the maximum LAD dose is less than 45.4 Gy,  
cardiac death from radiation by 10 years is low [16].  In 
this study,  18% (54/296) of the total,  37% (18/49) of W,  
15% (6/40) of W-FIF,  and 14% (30/207) of FIF cases 
had maximum LAD doses greater than 45.4 Gy.  From 
this,  FIF can be expected to reduce adverse heart events 
to a greater extent than conventional W.
As of 2016 in Japan [20],  FIF had become a main-
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　　PTV Mean dose (cGy) 0.37＊＊＊ (0.197,  0.523) 0.30＊ (0.069,  0.502) 0.08 (-0.014,  0.182) P<0.01ǂǂ
V0-95% -0.45＊＊＊ (-0.586,  -0.282) -0.33＊＊ (-0.528,  -0.104) -0.18＊＊＊ (-0.273,  -0.082) P<0.01ǂǂ
V95-107% 0.44＊＊＊ (0.281,  0.584) 0.33＊＊ (0.104,  0.528) 0.18＊＊＊ (0.083,  0.274) P<0.01ǂǂ
V107% 0.28＊＊ (0.099,  0.446) -0.26＊ (-0.464,  -0.020) 0.00 (-0.102,  0.096) P<0.001ǂ,  P<0.01ǂǂ,  P<0.05ǂǂǂ
V105% 0.20＊ (0.015,  0.376) 0.12 (-0.117,  0.350) 0.05 (-0.053,  0.144) NS
　　ALN Level I mean dose (cGy) 0.38＊＊＊ (0.205,  0.529) 0.40＊＊＊ (0.178,  0.580) 0.16＊＊ (0.060,  0.252) P<0.05ǂǂ, ǂǂǂ
Level II mean dose (cGy) 0.32＊＊＊ (0.143,  0.481) 0.38＊＊ (0.152,  0.562) 0.19＊＊＊ (0.096,  0.286) NS
Level III mean dose (cGy) 0.32＊＊＊ (0.139,  0.478) 0.36＊＊ (0.140,  0.553) 0.14＊＊ (0.047,  0.240) NS
　OAR
　　Lung ip mean dose (cGy) -0.32＊＊＊ (-0.476,  -0.137) -0.44＊＊＊ (-0.609,  -0.220) -0.29＊＊＊ (-0.378,  -0.197) NS
ipV20 (%) -0.36＊＊＊ (-0.518,  -0.190) -0.47＊＊＊ (-0.635,  -0.261) -0.32＊＊＊ (-0.403,  -0.225) NS
ipV30 (%) -0.34＊＊＊ (-0.495,  -0.160) -0.46＊＊＊ (-0.625,  -0.246) -0.31＊＊＊ (-0.401,  -0.223) NS
Patients of left breast cancer
　OAR
　　Heart Mean dose (cGy) 0.02 (-0.264,  0.298) 0.21 (-0.104,  0.493) 0.41＊＊＊ (0.288,  0.516) P<0.05ǂǂ
V10 (%) -0.03 (-0.310,  0.252) 0.19 (-0.124,  0.478) 0.26＊＊＊ (0.125,  0.380) NS
V20 (%) 0.03 (-0.261,  0.301) 0.28 (-0.044,  0.537) 0.27＊＊＊ (0.135,  0.388) NS
 LAD maximum dose (cGy) -0.02 (-0.303,  0.259) 0.26 (-0.052,  0.531) 0.03 (-0.104,  0.169) NS
CCA maximum dose (cGy) 0.13 (-0.156,  0.397) 0.05 (-0.267,  0.355) 0.53＊＊＊ (0.427,  0.624) P<0.01ǂǂ, ǂǂǂ
RCA maximum dose (cGy) -0.06 (-0.338,  0.222) -0.21 (-0.486,  0.114) 0.37＊＊＊ (0.248,  0.483) P<0.01ǂǂ,  P<0.001ǂǂǂ
＊,  P<0.05; ＊＊,  P<0.01; ＊＊＊,  P<0.001 for Spearmanʼs rank correlation coefficient,  respectively.
ǂ,  W vs W-FIF; ǂǂ,  W vs FIF; ǂǂǂ,  W-FIF vs FIF; NS,  not significant for Fisherʼs Z-transform for significant differences in rs,  respectively.  W,  wedge method; W-FIF,  wedge field-in-field 
method; FIF,  field-in-field method; rs,  Spearmanʼs rank correlation coefficient; CI,  confidence interval; PTV,  planning target volume; ALN,  axillary lymph node; OAR,  organ at risk; ip,  
ipsilateral pulmonary; LAD,  left anterior descending coronary artery; CCA,  left circumflex coronary artery; RCA,  right coronary artery.
stream method accounting for 39% of all radiotherapy 
treatments,  while the physical wedge method was 
reported to account for 29% and the dynamic wedge 
method for 28% of radiotherapy treatments; thus,  fur-
ther spread of FIF is desirable.  Ratosa et al.  stated that 
it is unclear whether a slight improvement in dosimetric 
parameters resulting from irradiation studies could 
reduce the incidence of clinically significant adverse 
events [13].  Further studies are needed to examine the 
relationship between the results of dosimetry parame-
ters and the occurrence of adverse events due to differ-
ences in irradiation methods.
In this retrospective study,  almost all patients who 
were treated in our hospital were analyzed by each irra-
diation method used sequentially for each era.  The 
limitation of this approach is that the bias of back-
ground factors for each group does not completely dis-
appear; however,  this bias of background factors might 
have been reduced by the large number of cases,  which 
exceeded 500.
In conclusion,  one of the key factors affecting dose 
distribution in breast cancer radiotherapy is the treated 
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Table 4　 Summary of dose parameters for each irradiation method
Irradiation method W W-FIF FIF Statistics (W vs W-FIF vs FIF)
All patients
　Patient 109 69 395
　Target
　　PTV Volume (cm3) 554±303 652±348 572±303 NS＊
Mean dose (cGy) 4,923±94 4,926±67 4,973±60 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
V0-95% 15±9 15±7 12±7 P<0.001＊ (P<0.01ǂǂ, P<0.001ǂǂǂ)
V95-107% 84±8 85±7 88±7 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
V107% 0.86±1.84 0.00±0.01 0.10±0.21 P<0.001＊ (P<0.001ǂ, ǂǂ, ǂǂǂ)
V105% 4.27±5.94 2.29±1.85 2.44±3.98 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
　　BPe Mean dose (cGy) 4,968±68 4,970±53 5,002±61 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
V0-95% 9±6 11±7 7±6 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
V95-107% 90±5 89±7 93±6 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
V107% 0.68±1.81 0.00±0.01 0.09±0.24 P<0.001＊ (P<0.01ǂǂǂ, P<0.001ǂ, ǂǂ)
V105% 3.84±5.93 2.31±2.06 2.55±4.32 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
　　ALN Mean dose (cGy)
Level I 2,966±731 2,869±695 3,368±805 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
Level II 1,365±998 1,341±1,084 1,552±1,209 NS＊
Level III 359±406 355±390 456±543 NS＊
　OAR
　　Lung ip mean dose (cGy) 683±186 621±156 729±206 P<0.001＊ (P<0.001ǂǂǂ)
ipV20 (%) 12±4 10±4 13±5 P<0.001＊ (P<0.05ǂǂ, P<  0.001ǂǂǂ)
ipV30 (%) 9±4 8±3 10±4 P<0.001＊ (P<0.01ǂǂ, P<  0.001ǂǂǂ)
Patients of left breast cancer
　Patient 49 40 207
　Target
　　PTV Volume (cm3) 608±323 613±324 566±308 NS＊
　OAR
　　Heart Mean dose (cGy) 304±117 295±72 251±81 P<0.001＊ (P<0.01ǂǂ, ǂǂǂ)
V10 (%) 4.0±3.4 3.7±2.2 3.0±2.3 P<0.05＊
V20 (%) 2.2±2.5 1.8±1.5 1.5±1.6 NS＊
LAD maximum dose (cGy) 3,478±1,351 3,629±1,069 3,058±1,388 P<0.05＊
CCA maximum dose (cGy) 240±34 238±31 205±32 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
RCA maximum dose (cGy) 263±73 259±34 218±37 P<0.001＊ (P<0.001ǂǂ, ǂǂǂ)
Number in “patient” indicates number of patient.  Number with “±” indicates mean with standard deviation.
＊,  Kruskal-Wallis test; ǂ,  W vs W-FIF; ǂǂ,  W vs FIF; ǂǂǂ,  W-FIF vs FIF for Scheffeʼs method of Kruskal-Wallis test,  respectively.
W,  wedge method; W-FIF,  wedge field-in-field method; FIF,  field-in-field method; PTV,  planning target volume;  NS, not significant; BPe,  
breast PTV evaluation; ALN,  axillary lymph node; OAR,  organ at risk; ip,  ipsilateral pulmonary; LAD,  left anterior descending coronary 
artery; CCA,  left circumflex coronary artery; RCA,  right coronary artery.
breast volume.  In the current study,  we examined irra-
diation methods according to breast volume in Asian 
breast cancer patients,  and compared the results with 
those in European and North American patients with 
larger breast volumes.  Our results revealed that FIF is 
less affected by breast volume than conventional irradi-
ation methods such as W,  and contributes to the uni-
formity of dose distribution for breasts of any size.
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